to review and potentially sanction centers that are considered to be underperforming. 2 The primary focus of quality assessment of transplant centers by regulatory agencies is risk-adjusted 1-year graft and patient survival. 2, 3 In general, there are several primary aims of healthcare provider report cards. These include a regulatory function to ensure quality performance, to provide objective feedback of performance and identify best practices, and to inform patients and other stakeholders regarding quality of providers. 2, 4, 5 The SRTR recently issued a 5-tier rating of transplant centers (with 5 indicating best outcomes and 1 indicating worst outcomes) based on centers' risk-adjusted 1-year graft survival. 6 The 5-tier rating replaced the traditional 3-tier rating system, which categorized center outcomes as "better than expected," "worse than expected,"
or "as expected." Part of the rationale to replace the 3-tier system was to provide more granular detailed information to stakeholders and to disseminate data to better inform patient decision-making in a more understandable format. 6 Following initial release of the 5-tier rating system, there were concerns raised by some members of the transplant community related to the utility and validity of the rating system. Based on these concerns, the 5-tier rating system was moved to a beta site linked to the primary SRTR website and still publicly accessible to patients and other stakeholders. 7 The ultimate use and accessibility of the 5-tier rating system is not clear at this time.
The primary aim of this study was to evaluate the variability of the 5-tier ratings for transplant centers over time. The rationale for the study was to assess the consistency of ratings as they would be utilized by stakeholders, particularly prospective transplant candidates to inform decision-making. Our hypothesis was that given the narrow margins of differences in graft survival between tier ratings, centers' ratings may change frequently thus limiting their utility for prospective decision-making. To evaluate temporal changes in 5-tier ratings, we retrospectively evaluated 10 consecutive 5-tier ratings of adult kidney transplant centers in the United States.
| METHODS
The data for the study derived from publicly available data including center-level outcomes from historic PSRs of all US transplant centers on the SRTR website. 1 Transplant center data were aggregated from worksheets available on the SRTR website for each of 10 PSRs from June 2012 to December 2016. For this study, we incorporated center-level data including transplant number, observed 1-year graft losses, and expected 1-year graft losses based on the applicable risk-adjusted graft survival models. We included centers that performed at least 1 transplant for each of the eligible cohorts in the study period. We retrospectively applied the 5-tier rating using the hazard ratio and expected events at intervals of 0.25 based on the algorithm supplied by the SRTR to prior PSRs. Consistent with current SRTR methodology, the hazard ratio incorporates a shrinkage factor and is calculated as a ratio: (observed events + 2)/(expected events +2). 8 To evaluate the stability of 5-tier ratings for transplant centers, we considered the June 2012 report as the "baseline period" and evaluated changes (eg, at least 1 unit) in the 5-tier outcomes assessment over each consecutive PSR. We used Kaplan-Meier methodology to assess time to change in the 5-tier rating from the baseline period, with a maximum follow-up period of 54 months (9 follow-up PSRs).
We repeated models with time to a 2-unit change in the 5-tier rat- At least one low 3-tier rating, n (%) 24 (12) At least one high 3-tier rating, n (%) 34 (16) Always "As expected," n (%) 150 (72)
Median number of different 5-tier ratings, median (q1, q3) 3 (2, 4) Centers with at least one 5-tier rating = 1, n (%) 46 (22) Centers with at least one 5-tier rating = 2, n (%) 147 ( Table 1 ). Over the course of the study period, 150 centers (72%) had 1-year graft survival outcomes that were "as expected" for all 10 periods based on the 3-tier rating. Twenty-four (12%) of centers had a least 1 low 3-tier rating indicating "lower than expected" outcomes and 34 (16%) had at least 1 high 3-tier rating indicating "higher than expected" during the study period.
Among the 208 centers, 8 (4%) had the same 5-tier rating throughout the period, 52 (25%) had 2 different tier ratings, 8 9(43%) had 3 different tier ratings, 52 (25%) had 4 different tier ratings, and 7 (3%)
had each of the 5-tier ratings during the study period. The median number of different 5-tier ratings per transplant center was 3 (25th percentile = 2, 75th percentile = 4. During the study period, 46 centers (22%) had at least one 1-tier rating, 147 (71%) had at least one 2-tier rating, 175 (84%) had at least one 3-tier rating, 169 (81%) had at least one 4-tier rating, and 85 (41%) had at least one 5-tier rating (Table 1) .
Considering the June 2012 PSR as the baseline period, 200 of the 208 (96%) centers had a change in rating over the study period. (Table 3) .
| DISCUSSION
The primary findings of the study indicate that the 5-tier rating of adult kidney transplant centers vary significantly over time within individual transplant centers. Almost half of programs have a shift in 5-tier rating within 1 PSR cycle (6 months), and most centers (94%) have a tier shift within 3 years. Moreover, more than half of programs shift at least 2 tiers within 4 years. These findings are important as one of the primary purposes and motivations of the 5-tier ratings is to present data to stakeholders, in particular patients, to inform decisionmaking. Currently, less than 25% of patients receive a deceased donor transplant in less than 3 years and median waiting times exceed 4 years in the United States. 9 Results of this study indicate that decisions to select centers based on 5-tier ratings at a given point may often be obsolete in a short duration after placement on the waiting list. Further consideration of more robust transplant center quality metrics that can reliably be utilized to inform patients and other stakeholders are needed.
One of the likely reasons for the frequent fluctuations in transplant center 5-tier ratings is the narrow difference in graft survival rates between each of the tiers. Based on analyses by the SRTR, the average difference between each of the tier ratings is approximately 1.5% graft survival at 1 year. 6 For many programs, this may represent 1 or 2 graft losses for a 2.5-year cohort of transplant recipients. Thus the likelihood that a center will continue to perform as a stable tier program is poor given many frequent unexpected causes of graft loss in the transplant population. As depicted in this study, virtually all programs alter their 5-tier rating within 3 years, and the majority of centers alter their rating by at least 2 tiers. Moreover, based on the analyses conducted by the SRTR to develop the 5-tier ratings, even the simulated probability that there is an actual difference between tiers is fairly modest, particularly between adjacent levels, which include a 63% and 66%
probability of an actual difference between tiers 3 and 4 and 2 and The variation in ratings is also likely affected by the fact that the models used to estimate the expected events for the calculation of the 5-tier ratings has a relatively modest predictive capacity. 10 This limited predictive accuracy coupled with empirical studies that document underlying (nonadjusted) factors that impact graft outcomes, suggest that deviations in outcomes may not consistently be attributed to center quality of care. [11] [12] [13] To place the findings of this study in perspective, it is unlikely that approximately 50% of programs have significant shifts in actual quality of care within a 6-month period as the 5-tier ratings suggest. Thus, there is significant likelihood that variations in 5-tier ratings reflect random variations or are based on noncodified factors rather than true variation in quality of care. 14 The degree to which the stability of the models may be improved with current available risk adjustment or by updating the posterior probability distribution used for the models is not clear. However, the current models are also uniformly volatile by center volume, transplant rate, and initial quality tier,
suggesting that different statistical techniques may not remedy this variation.
There are several factors and secular changes associated with the current findings that should also be considered. First, the timeline of the current simulations included significant changes in risk adjustment and as such may have shifted some of the measured quality of centers based the use of additional factors in the models. In addition, the introduction of the cumulative sum models also occurred during the study period and may have altered behavior or outcomes that were reflected in reports. Moreover, the hiatus in reports in 2012 may have obscured programs' knowledge about their own outcomes and any potential changes in practice associated with measured quality. Although each of these factors applied to all centers in the study over the study period, it is possible that they could have contributed to alteration in measured quality over time.
Perhaps the more important concern with the current assessment of transplant centers are the primary endpoints that are considered to evaluate the quality of care. Currently, the primary outcome measures of 1-year graft and patient survival represent only a component of overall transplant center care. For example, measures that account for access to transplantation and care provided prior to transplantation and beyond 1-year posttransplantation may provide more accurate assessment of quality, and these measures may be more impactful to patient prognoses and more robust over time.
In fact, a prior study demonstrated that for prospective transplant candidates, transplant centers' median waiting time for receiving a transplant had a much more pronounced effect on long-term patient survival than transplant centers' 1-year posttransplantation survival rates. 15 Thus although 1-year survival may be an indicator of quality in a specific period, it may be only a modest factor relative to other center characteristics that affect patient outcomes. 16 Notably, even the 3-tier rating of center quality differentiates centers with minor differences in clinical outcomes, and these differences are incremental relative to expected outcomes for patients that do not receive a transplant.
17,18
Placing the study findings in context of an ideal report card for transplant centers suggests several concerns. Given the rapid fluctuations in ratings, it is not clear that they are useful for regulatory oversight, as changes that are identified in one period may be quickly obsolete prior to any implementation of an intervention. Similarly, the deduction of best practices based on 5-tier ratings may be unfounded and may be unable to distinguish observations associated with quality and random variations. Finally,, and perhaps most importantly, the use of these data by patients as a guide for accessing higher quality centers appears problematic given the time to transplant for most patients and the discordance of ratings for most patients in this interval.
Another important consideration for the introduction of quality metrics, particularly in the public domain, is the potential for unintended consequences. As these data are utilized by a variety of stakeholders, the intended benefits of evaluating the quality of programs must be balanced by the way these data may alter practice that may not be concordant with best practices. Several studies have demonstrated significant changes in transplant volume, transplant rates, and candidate removals associated with current quality oversight. [19] [20] [21] [22] These changes have generally been ascribed to increases in risk aversion, reluctance to innovate in a punitive environment, and the austere consequences of receiving low performance evaluations. 4, [22] [23] [24] The degree to which the 5-tier ratings may change or exacerbate these consequences is not currently known given their recent introduction. However, given the volatility of the ratings, significantly more programs are assessed with lower ratings at some point as compared to the traditional 3-tier assessment. Thus, the attempt to further differentiate transplant centers with the 5-tier assessment may lead to even more frequent unintended behavior changes such as increased organ discards, more selective candidate listings, and reduced transplant rates.
Overall, given the frequent fluctuations of the 5-tier ratings, the incremental clinical differences between each tier, the limited utility of ratings for center selection, and the potential for heightened unintended consequences, the 5-tier ratings system does not appear to offer clear benefits and may exacerbate existing problems with quality oversight. Rather than efforts focused on developing more granular assessments of 1-year survival outcomes, which are already largely clustered between centers, further efforts to evolve endpoints as a metric for center quality is a much greater imperative. The transplant community may consider broader outcome assessments that are indicative of quality care beyond the transplant episode that extend through transitions of care (eg, pre-transplantation and longer posttransplantation metrics). It is important to note that these metrics should be directly aligned with long-term outcomes for patients with end-stage organ disease. [25] [26] [27] Further research and policy efforts to 
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